ATAi Ling Tan

Ai Ling Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ai Ling Tan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The PASE Study: The Prevalence and Associations of Bendopnoea in Patients with Pneumothorax

    by Bianca M. Iacopetta, Niranjan Ananda Setty, Chloe Charlesworth, Michaela Donaghy, Carolyn J. Peddle-McIntyre, Ai Ling Tan, Y. C. Gary Lee

    Background: We recently established that bendopnoea (breathlessness upon bending forward) is common with pleural effusion; however, it has never been reported or investigated in patients with pneumothorax. This exploratory study investigated the prevalence and clinical relevance of bendopnoea in pneumothorax. Methods: Patients with pneumothorax of any aetiology or size were eligible. The presence of bendopnoea and time-to-bendopnoea was measured by bending the patient forward for 60 s and was assessed at baseline and post lung re-expansion. Results: Fifty patients (median age 48 years; 78% male) with primary spontaneous (48%), secondary spontaneous (24%) or iatrogenic (28%) pneumothorax were included. Pneumothorax size ranged from 7 to 99% of the hemithorax on chest radiographs. Most patients (74%) received conservative management. On a questionnaire, 48% (24/50) patients reported they experienced bendopnoea which “impacted daily life”. When bent forward, 32% (16/50) developed bendopnoea within 60 s. Patients with bendopnoea reported more breathlessness than those without bendopnoea on a 100 mm Visual Analogue Scale (VAS): median 46 [Q1–Q3 = 25–54] vs. 12 [3–32] mm, respectively, p = 0.0089; median difference −23 mm (95% CI −35 to −6). Those with bendopnoea showed a signal with worse chest pain on a 100 mm VAS for pain: median 28 [13–48] vs. 10 [2–42] mm, p = 0.0528; median difference −15 mm (95% CI −27 to 0). Shorter time-to-bendopnoea (i.e., worse bendopnoea) correlated with worse breathlessness (rs = −0.38, 95% CI −0.6 to −0.1; p = 0.0072) and more severe chest pain (rs = −0.29, 95% CI −0.5 to −0.007; p = 0.039). Conclusions: Bendopnoea can occur with pneumothorax, correlates with breathlessness and demonstrates a signal with worse chest pain.

  • Open Access

    Study Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time ( EVAPoRATe ) Pilot Multicentre Randomised Clinical Trial

    by Nai‐Chien Huan, Niranjan Ananda Setty, Ai Ling Tan, Dhaval Thakkar, Taha Huseini, Elaine Yap, Jonathan Williamson, Phan Nguyen, Paul Lilburn, Matthew Salamonsen, et al.

    Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital‐acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open‐labelled, pilot, multi‐centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow‐up. Secondary outcomes include total hospital length of stay, PAL‐related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full‐scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true

  • Open Access

    A Parallel Group, 1:1 Randomised, Pilot Study Comparing the Clinical Efficacy and Bleeding Risk Between Low Dose and Standard Dose Intrapleural Tissue Plasminogen Activator for Adults With Pleural Infection

    by Ken Ka Pang Chan, Christopher Chan, David Shu Cheong Hui, Ai Ling Tan, Y. C. Gary Lee

    Background: A pilot study to assess the feasibility of a randomization trial protocol comparing low (2.5 mg) and standard (10 mg) doses of intrapleural tissue plasminogen activator (tPA) with deoxyribonucleases (DNase) in unresolved pleural infection. The proposed protocol comparing low‐dose and standard doses of intrapleural tPA (with DNase) therapy will be feasible and acceptable. Methods: A single‐centre, two‐arm, double‐blinded, randomised controlled feasibility study which includes subjects with unresolved pleural infection eligible for intrapleural tPA/DNase injection, with follow‐ups till 3 months after hospital discharge. Recruited subjects will be randomised in a 1:1 ratio to receive a maximum of 6 doses of intrapleural tPA (with DNase) starting at either 2.5 or 10 mg. A clinical decision is allowed at or after the third dose of tPA to continue the assigned regimen (blinded) or convert to open‐label use of 10 mg doses of tPA to complete the course based on the clinical response. Discussion: The main outcome is the feasibility of the trial protocol, based on the percentage of eligible patients enrolled, retained to discharge, and completing 3 months of follow‐up. Other important outcomes include survival at 3 months follow‐up and without the need for surgical intervention, the need for additional pleural interventions, the number of decisions to convert to open‐labelled use of 10 mg intrapleural tPA, clinical and radiographic response after the treatment course, safety profiles, especially bleeding complications and the number and reason for protocol violation. Feasibility outcomes will be reported as descriptive data. Comparison of outcomes between the two treatment groups will be analysed on an intention‐to‐treat basis. Safety outcomes will be reported descriptively for each group. The reported estimates of recruitment rates, adherence, follow‐up completeness, and variability and event rates for key clinical and bleeding outcomes will inform the design of future studies that incorporate the current study design. Trial registration: NCT05766124, ClinicalTrials.gov

  • Open Access

    Integrative Supportive Care Trial to Enhance Physical Activity in Malignant Pleural Effusion—Protocol for the ISC‐TEAM/AMPLE‐5 Randomised Controlled Trial

    by Bianca M. Iacopetta, Chloe Charlesworth, Emily Jeffery, Lauren J. Breen, Ai Ling Tan, Joanne McVeigh, Kevin Murray, Rob U. Newton, Y. C. Gary Lee, Carolyn J. Peddle‐Mcintyre

    Background: Malignant pleural effusion (MPE) heralds advanced cancer with poor patient outcomes. High symptom burden of weight loss, fatigue, breathlessness, distress, and anxiety leaves many patients unable to participate in desired activities of daily life and is associated with poor outcomes. Freedom from symptoms and maintaining daily activities are the key wishes of patients and carers. For the best outcome, accessible services aimed at prevention and management of malnutrition, care of psychological well‐being, and support for increasing physical activity are required.Methods: The Integrative Supportive Care Trial to Enhance physical Activity in Malignant pleural effusion (ISC‐TEAM) study is a two‐armed, parallel group randomised controlled trial. Participants (n = 100) diagnosed with MPE will be randomly assigned to receive standard clinical care or integrative supportive care. Integrative supportive care will entail an individualised multidisciplinary program of dietetics, exercise physiology, and psychological input over 12 weeks. Participants will receive telehealth consultations with each discipline at week 1, week 4, and week 8. The primary outcome is device‐assessed daily physical activity (steps/day). Secondary outcomes include quality of life, malnutrition risk, psychopathology, symptoms, physical activity profile, and program acceptability and compliance.Discussion: This randomised trial will evaluate the effects of a multidisciplinary supportive care program in MPE aimed at improving participants ability to engage in physical activities.Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12624000038594; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386529&isReview=true

  • Open Access

    The Pneumothorax And Symptom Evaluation (PASE) study: Bendopnoea in patients with pneumothorax

    by Bianca M. Iacopetta, Michaela Donaghy, Chloe Charlesworth, Carolyn J. Peddle‐McIntyre, Ai Ling Tan, Y. C. Gary Lee

    Background: Pneumothorax can cause distressing breathlessness, however the effect of the accumulated air in the pleural space and its association with diaphragmatic function and symptoms of breathlessness is not well understood. Bendopnoea is an evolving clinical symptom that has been demonstrated as clinically useful in some heart and lung conditions. Whether bendopnoea is present in patients with pneumothorax, and its potential clinical usefulness has not yet been investigated. The PASE study is a pilot study to explore the incidence and clinical relevance of bendopnoea in patients with pneumothorax and may provide better understanding of pneumothorax related dyspnoea.Methods: PASE is a prospective study. Eligible patients are assessed at baseline (pre air drainage/lung reinflation) and in patients whose pneumothorax resolves once the lung has re‐expanded (post conservative management or air drainage procedure). Outcome measures include the incidence of bendopnoea, correlation of the associated symptoms (pain and breathlessness) to the severity of bendopnoea and the size of pneumothorax; and correlation with clinical outcome (i.e., response to air drainage/lung reinflation). The study will recruit 50 participants.Discussion: This is the first study to explore bendopnoea in patients with pneumothorax. The presence and significance of bendopnoea in relation to clinical and physiological parameters in patients with pneumothorax requires investigation. The findings of this study may further current understanding of dyspnoea related pneumothorax.Trial Registration: Name of the registry: Australia New Zealand Clinical Trial RegistryTrial registration number: ACTRN12623001109695p.URL of the trial registry record for this trial: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386631&isReview=trueDate of registration: Registered on 24 October 2023.Funding of the trial: This study has not received grant support. The study is sponsored by the Institute for Respiratory Health, a not‐for‐profit organisation.Name and contact information for the trial sponsor: Mr Bi Lam; Finance manager. Level 2, 6 Verdun Street, Nedlands, WA 6009.Role of sponsor: The funder is not involved in the planning of the study, gathering, analysing, and interpreting the data, or in preparing the manuscript.Protocol version: 1.


  • Open Access

    Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion

    by Deirdre B. Fitzgerald, Calvin Sidhu, Charley Budgeon, Ai Ling Tan, Catherine A. Read, Benjamin C. H. Kwan, Nicola Ann Smith, Edward T. Fysh, Sanjeevan Muruganandan, Tajalli Saghaie, et al.

    Introduction: Malignant pleural effusions (MPEs) are common. MPE causes significant breathlessness and impairs quality of life. Indwelling pleural catheters (IPC) allow ambulatory drainage and reduce hospital days and re-intervention rates when compared to standard talc slurry pleurodesis. Daily drainage accelerates pleurodesis, and talc instillation via the IPC has been proven feasible and safe. Surgical pleurodesis via video-assisted thoracoscopic surgery (VATS) is considered a one-off intervention for MPE and is often recommended to patients who are fit for surgery. The AMPLE-3 trial is the first randomised trial to compare IPC (±talc pleurodesis) and VATS pleurodesis in those who are fit for surgery. Methods and analysis: A multi-centre, open-labelled randomised trial of patients with symptomatic MPE, expected survival of ≥ 6 months and good performance status randomised 1:1 to either IPC or VATS pleurodesis. Participant randomisation will be minimised for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis (vs not); and (iii) trapped lung, if known (vs not). Primary outcome is the need for further ipsilateral pleural interventions over 12 months or until death, if sooner. Secondary outcomes include days in hospital, quality of life (QoL) measures, physical activity levels, safety profile, health economics, adverse events, and survival. The trial will recruit 158 participants who will be followed up for 12 months. Ethics and dissemination: Sir Charles Gairdner and Osborne Park Health Care Group (HREC) has approved the study (reference: RGS356). Results will be published in peer-reviewed journals and presented at scientific meetings. Discussion: Both IPC and VATS are commonly used procedures for MPE. The AMPLE-3 trial will provide data to help define the merits and shortcomings of these procedures and inform future clinical care algorithms. Trial registration: Australia New Zealand Clinical Trial Registry ACTRN12618001013257. Registered on 18 June 2018. Protocol version: Version 3.00/4.02.19